Nephros Inc (NEPH) 0.5000 $NEPH
Nephros Reports Second Quarter 2016 Financial Results
ACCESSWIRE - Mon Aug 08, 6:42AM CDT
RIVER EDGE, NJ / ACCESSWIRE / August 8, 2016 / Nephros, Inc. (OTCQB: NEPH), (the "Company"
a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration ("HDF" system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, today announced financial results for the three months ended June 30, 2016.
Nephros Announces Closing of $1.2 Million Note and Warrant Offering
ACCESSWIRE - Thu Jun 09, 3:30PM CDT
RIVER EDGE, NJ / ACCESSWIRE / June 9, 2016 / Nephros, Inc. (OTCQB: NEPH) (the "Company", a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced today that it has completed a private placement of unsecured promissory notes and warrants to purchase the Company's common stock resulting in total gross proceeds to the Company of approximately $1.2 million.
Nephros Announces Distribution Agreement with CS Medical, LLC
ACCESSWIRE - Mon May 23, 6:30AM CDT
RIVER EDGE, NJ / ACCESSWIRE / May 23, 2016 / Nephros, Inc. (OTCQB: NEPH), (the "Company" a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, announced today that it has signed a distribution agreement with CS Medical, LLC, a leader in developing, manufacturing, and marketing medical devices designed to provide high-level disinfection of ultrasound Trans-Esophageal Echocardiogram ("TEE" probes.
Nephros Announces Submission of Special 510(k) Application to the FDA for the EndoPur(TM) Ultrafilter
ACCESSWIRE - Thu Apr 21, 6:30AM CDT
RIVER EDGE, NJ / ACCESSWIRE / April 21, 2016 / Nephros, Inc. (OTCQB: NEPH), (the "Company" a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration ("HDF" system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced today that it has submitted a Special 510(k) application to the U.S. Food and Drug Administration (FDA) for its EndoPur(TM) ultrafilter designed to provide hemodialysis quality water.
Nephros Receives FDA 510(k) Clearance of S100 Point of Use Filter
ACCESSWIRE - Thu Apr 14, 6:30AM CDT
RIVER EDGE, NJ / ACCESSWIRE / April 14, 2016 / Nephros, Inc. (OTCQB:NEPH), (the "Company" a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration ("HDF" system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration ("FDA" to market its S100 Point of Use filter designed to filter Environmental Protection Agency ("EPA" quality drinking water to retain waterborne bacteria to assist in infection control.
SeeThruEquity Issues Update on Nephros, Inc. (OTCQB: NEPH)
ACCESSWIRE - Wed Apr 06, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / April 6, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update note on Nephros, Inc. (OTCQB: NEPH).
Nephros publishes observational trial of DSU-D in Hospital-Based Dialysis Facility in Nephrology and Dialysis
M2 - Tue Jan 19, 4:50AM CST
Medical device company Nephros (OTCBB:NEPH) said on Monday that data about its DSU-D ultrafilter was published online in Case Reports in Nephrology and Dialysis.
SeeThruEquity Issues Company Update On Nephros, Inc. (OTCQB: NEPH)
ACCESSWIRE - Mon Nov 30, 8:02AM CST
NEW YORK, NY / ACCESSWIRE / November 30, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a company update on Nephros, Inc. (OTCQB: NEPH).
Nephros to Present at the LD Micro Main Event
ACCESSWIRE - Tue Nov 24, 8:20AM CST
LOS ANGELES, CA / ACCESSWIRE / November 24, 2015 / Nephros (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, today announced that it will be presenting at the 8th annual LD Micro Main Event on Tuesday, December 1st at 3 PM PST / 6 PM EST. President and CEO and Nephros, Daron Evans, will be giving the presentation and meeting with investors.
Nephros submits S100 Ultrafilter to US FDA for control of infection in medical facilities
M2 - Wed Oct 28, 6:08AM CDT
Medical device company Nephros (OTCBB:NEPH) said on Tuesday that it has submitted the S100 Point of Use filter designed to filter Environmental Protection Agency (EPA) quality drinking water to retain waterborne bacteria to assist in infection control for US Food and Drug Administration (FDA) 510(k) clearance.
Nephros hires Moshe Pinto to board
M2 - Tue Aug 18, 6:04AM CDT
Medical device company Nephros (OTCBB:NEPH) revealed on Monday that Moshe Pinto has been appointed to its board of directors.
Nephros, Inc. Enters Into Purchase Agreement with Lincoln Park Capital Fund, LLC
BusinessWire - Mon Jul 27, 6:30AM CDT
Nephros, Inc. (OTCBB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration ("HDF" system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced today that it has entered into a purchase agreement with Lincoln Park Capital Fund, LLC ("LPC", a Chicago-based institutional investor. Under the terms of the purchase agreement, over a 36-month term, Nephros will have the right and the sole discretion to sell to LPC up to $10 million worth of shares of Nephros common stock in amounts as set forth in the agreement. Nephros will control the timing and amount of any future investment and LPC will be obligated to make purchases in accordance with the agreement.
SeeThruEquity Initiates Coverage on Nephros, Inc. (OTCBB: NEPH) with Price Target of $1.65
ACCESSWIRE - Thu Jun 04, 7:57AM CDT
NEW YORK, NY / ACCESSWIRE / June 4, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of Nephros, Inc. (OTCQB: NEPH) with Price Target of $1.65.
Nephros posts higher net operating loss of USD806,000 for Q1 2015
M2 - Mon May 18, 5:17AM CDT
Medical device company Nephros (OTCBB:NEPH) disclosed on Friday that it recorded a net operating loss of USD806,000 for the three months ended 31 March 2015.
Nephros expects USD1.2m from private placement of common shares
M2 - Wed May 13, 6:57AM CDT
Medical device company Nephros (OTCBB:NEPH) reported on Tuesday the launch of definitive agreements for the sale of about USD1.2m of its common stock.
Nephros hires Malcolm Persen to board
M2 - Mon May 11, 7:31AM CDT
Medical device company Nephros (OTCBB:NEPH) disclosed on Friday the addition appointment of Malcolm Persen to its board of directors, including chair of the Audit Committee.
Nephros signs HydraGuard military filter licensing agreement with CamelBak
M2 - Thu May 07, 5:15AM CDT
Medical device company Nephros (OTCBB:NEPH) reported on Wednesday that it has granted the exclusive license to its HydraGuard military filter to CamelBak for an undisclosed value.
Nephros Provides Corporate Update
BusinessWire - Mon Dec 08, 3:49PM CST
Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of chronic renal failure patients, today provided an update on its operations and strategy.
Nephros Reports Second Quarter 2016 Financial Results
ACCESSWIRE - Mon Aug 08, 6:42AM CDT
RIVER EDGE, NJ / ACCESSWIRE / August 8, 2016 / Nephros, Inc. (OTCQB: NEPH), (the "Company"
a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration ("HDF" system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, today announced financial results for the three months ended June 30, 2016. Nephros Announces Closing of $1.2 Million Note and Warrant Offering
ACCESSWIRE - Thu Jun 09, 3:30PM CDT
RIVER EDGE, NJ / ACCESSWIRE / June 9, 2016 / Nephros, Inc. (OTCQB: NEPH) (the "Company"
, a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced today that it has completed a private placement of unsecured promissory notes and warrants to purchase the Company's common stock resulting in total gross proceeds to the Company of approximately $1.2 million. Nephros Announces Distribution Agreement with CS Medical, LLC
ACCESSWIRE - Mon May 23, 6:30AM CDT
RIVER EDGE, NJ / ACCESSWIRE / May 23, 2016 / Nephros, Inc. (OTCQB: NEPH), (the "Company"
a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, announced today that it has signed a distribution agreement with CS Medical, LLC, a leader in developing, manufacturing, and marketing medical devices designed to provide high-level disinfection of ultrasound Trans-Esophageal Echocardiogram ("TEE" probes. Nephros Announces Submission of Special 510(k) Application to the FDA for the EndoPur(TM) Ultrafilter
ACCESSWIRE - Thu Apr 21, 6:30AM CDT
RIVER EDGE, NJ / ACCESSWIRE / April 21, 2016 / Nephros, Inc. (OTCQB: NEPH), (the "Company"
a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration ("HDF" system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced today that it has submitted a Special 510(k) application to the U.S. Food and Drug Administration (FDA) for its EndoPur(TM) ultrafilter designed to provide hemodialysis quality water. Nephros Receives FDA 510(k) Clearance of S100 Point of Use Filter
ACCESSWIRE - Thu Apr 14, 6:30AM CDT
RIVER EDGE, NJ / ACCESSWIRE / April 14, 2016 / Nephros, Inc. (OTCQB:NEPH), (the "Company"
a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration ("HDF" system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration ("FDA" to market its S100 Point of Use filter designed to filter Environmental Protection Agency ("EPA" quality drinking water to retain waterborne bacteria to assist in infection control. SeeThruEquity Issues Update on Nephros, Inc. (OTCQB: NEPH)
ACCESSWIRE - Wed Apr 06, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / April 6, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update note on Nephros, Inc. (OTCQB: NEPH).
Nephros publishes observational trial of DSU-D in Hospital-Based Dialysis Facility in Nephrology and Dialysis
M2 - Tue Jan 19, 4:50AM CST
Medical device company Nephros (OTCBB:NEPH) said on Monday that data about its DSU-D ultrafilter was published online in Case Reports in Nephrology and Dialysis.
SeeThruEquity Issues Company Update On Nephros, Inc. (OTCQB: NEPH)
ACCESSWIRE - Mon Nov 30, 8:02AM CST
NEW YORK, NY / ACCESSWIRE / November 30, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a company update on Nephros, Inc. (OTCQB: NEPH).
Nephros to Present at the LD Micro Main Event
ACCESSWIRE - Tue Nov 24, 8:20AM CST
LOS ANGELES, CA / ACCESSWIRE / November 24, 2015 / Nephros (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, today announced that it will be presenting at the 8th annual LD Micro Main Event on Tuesday, December 1st at 3 PM PST / 6 PM EST. President and CEO and Nephros, Daron Evans, will be giving the presentation and meeting with investors.
Nephros submits S100 Ultrafilter to US FDA for control of infection in medical facilities
M2 - Wed Oct 28, 6:08AM CDT
Medical device company Nephros (OTCBB:NEPH) said on Tuesday that it has submitted the S100 Point of Use filter designed to filter Environmental Protection Agency (EPA) quality drinking water to retain waterborne bacteria to assist in infection control for US Food and Drug Administration (FDA) 510(k) clearance.
Nephros hires Moshe Pinto to board
M2 - Tue Aug 18, 6:04AM CDT
Medical device company Nephros (OTCBB:NEPH) revealed on Monday that Moshe Pinto has been appointed to its board of directors.
Nephros, Inc. Enters Into Purchase Agreement with Lincoln Park Capital Fund, LLC
BusinessWire - Mon Jul 27, 6:30AM CDT
Nephros, Inc. (OTCBB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration ("HDF"
system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced today that it has entered into a purchase agreement with Lincoln Park Capital Fund, LLC ("LPC", a Chicago-based institutional investor. Under the terms of the purchase agreement, over a 36-month term, Nephros will have the right and the sole discretion to sell to LPC up to $10 million worth of shares of Nephros common stock in amounts as set forth in the agreement. Nephros will control the timing and amount of any future investment and LPC will be obligated to make purchases in accordance with the agreement. SeeThruEquity Initiates Coverage on Nephros, Inc. (OTCBB: NEPH) with Price Target of $1.65
ACCESSWIRE - Thu Jun 04, 7:57AM CDT
NEW YORK, NY / ACCESSWIRE / June 4, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of Nephros, Inc. (OTCQB: NEPH) with Price Target of $1.65.
Nephros posts higher net operating loss of USD806,000 for Q1 2015
M2 - Mon May 18, 5:17AM CDT
Medical device company Nephros (OTCBB:NEPH) disclosed on Friday that it recorded a net operating loss of USD806,000 for the three months ended 31 March 2015.
Nephros expects USD1.2m from private placement of common shares
M2 - Wed May 13, 6:57AM CDT
Medical device company Nephros (OTCBB:NEPH) reported on Tuesday the launch of definitive agreements for the sale of about USD1.2m of its common stock.
Nephros hires Malcolm Persen to board
M2 - Mon May 11, 7:31AM CDT
Medical device company Nephros (OTCBB:NEPH) disclosed on Friday the addition appointment of Malcolm Persen to its board of directors, including chair of the Audit Committee.
Nephros signs HydraGuard military filter licensing agreement with CamelBak
M2 - Thu May 07, 5:15AM CDT
Medical device company Nephros (OTCBB:NEPH) reported on Wednesday that it has granted the exclusive license to its HydraGuard military filter to CamelBak for an undisclosed value.
Nephros Provides Corporate Update
BusinessWire - Mon Dec 08, 3:49PM CST
Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of chronic renal failure patients, today provided an update on its operations and strategy.
